The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| GPCR | -14.37% | N/A | N/A | +26% |
| S&P | +12.65% | +91.73% | +13.89% | +63% |
Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company engaged in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. The company was founded by Raymond Stevens in February 2019 and is headquartered in San Francisco, CA.
We should know a lot more by year-end.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.85M | -268.5% |
| Market Cap | $1.19B | -46.7% |
| Market Cap / Employee | $6.00M | -63.6% |
| Employees | 199 | 46.3% |
| Net Income | -$61.88M | -138.0% |
| EBITDA | -$69.84M | -111.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $147.03M | -61.5% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $5.01M | 64.6% |
| Short Term Debt | $2.66M | 63.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -20.34% | -3.3% |
| Return On Invested Capital | -35.57% | 5.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$54.98M | -105.2% |
| Operating Free Cash Flow | -$54.75M | -107.6% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.73 | 1.73 | 1.15 | 1.45 | -66.02% |
| Price to Tangible Book Value | 2.73 | 1.73 | 1.15 | 1.45 | -66.02% |
| Enterprise Value to EBITDA | -34.83 | -14.97 | -2.93 | -5.94 | -80.72% |
| Return on Equity | -20.4% | -18.6% | -22.9% | -21.2% | 19.66% |
| Total Debt | $4.39M | $3.86M | $7.59M | $7.68M | 64.23% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
